GEAP202316262A - Pharmaceutical compositions of a kinase inhibitor - Google Patents

Pharmaceutical compositions of a kinase inhibitor

Info

Publication number
GEAP202316262A
GEAP202316262A GEAP202316262A GEAP2023016262A GEAP202316262A GE AP202316262 A GEAP202316262 A GE AP202316262A GE AP202316262 A GEAP202316262 A GE AP202316262A GE AP2023016262 A GEAP2023016262 A GE AP2023016262A GE AP202316262 A GEAP202316262 A GE AP202316262A
Authority
GE
Georgia
Prior art keywords
pharmaceutical compositions
kinase inhibitor
methods
relates
pharmaceutical composition
Prior art date
Application number
GEAP202316262A
Other languages
English (en)
Georgian (ka)
Inventor
Iswadi Liejanto
Tzu-Yuan Chen
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of GEAP202316262A publication Critical patent/GEAP202316262A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GEAP202316262A 2020-11-05 2021-11-04 Pharmaceutical compositions of a kinase inhibitor GEAP202316262A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063110124P 2020-11-05 2020-11-05

Publications (1)

Publication Number Publication Date
GEAP202316262A true GEAP202316262A (en) 2023-08-10

Family

ID=78820880

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP202316262A GEAP202316262A (en) 2020-11-05 2021-11-04 Pharmaceutical compositions of a kinase inhibitor

Country Status (16)

Country Link
US (1) US20230398108A1 (enExample)
EP (1) EP4240333A1 (enExample)
JP (1) JP2023548855A (enExample)
KR (1) KR20230104186A (enExample)
CN (1) CN116406261A (enExample)
AU (1) AU2021374669A1 (enExample)
CA (1) CA3196001A1 (enExample)
CL (1) CL2023001268A1 (enExample)
CO (1) CO2023005942A2 (enExample)
CR (1) CR20230223A (enExample)
GE (1) GEAP202316262A (enExample)
IL (1) IL302485A (enExample)
MX (1) MX2023005273A (enExample)
PE (1) PE20240223A1 (enExample)
TW (1) TW202227061A (enExample)
WO (1) WO2022098828A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEAP202415420A (en) * 2018-01-26 2024-12-25 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
AR127561A1 (es) * 2021-11-03 2024-02-07 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009722A1 (en) * 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
US11564915B2 (en) * 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
WO2016079687A1 (en) * 2014-11-18 2016-05-26 Lupin Limited Oral pharmaceutical composition of teriflunomide
GEAP202415420A (en) 2018-01-26 2024-12-25 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
EP4631505A3 (en) 2018-12-13 2025-12-10 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
US20220072002A1 (en) * 2018-12-24 2022-03-10 Chia Tai Tianqing Pharmaceuticalgroup Co., Ltd. Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound

Also Published As

Publication number Publication date
PE20240223A1 (es) 2024-02-16
JP2023548855A (ja) 2023-11-21
WO2022098828A1 (en) 2022-05-12
CL2023001268A1 (es) 2023-12-11
CA3196001A1 (en) 2022-05-12
CR20230223A (es) 2023-07-07
CO2023005942A2 (es) 2023-05-19
EP4240333A1 (en) 2023-09-13
TW202227061A (zh) 2022-07-16
KR20230104186A (ko) 2023-07-07
AU2021374669A9 (en) 2024-04-18
CN116406261A (zh) 2023-07-07
MX2023005273A (es) 2023-05-23
IL302485A (en) 2023-06-01
US20230398108A1 (en) 2023-12-14
AU2021374669A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
PH12021551356A1 (en) Crystalline forms and salt forms of a kinase inhibitor
SA522431915B1 (ar) Prmt5 مثبطات mta تعاونية مع
CO2025015814A2 (es) Inhibidores de kras de 2-azabiciclo [2.2.1] heptano
MX2021005047A (es) Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
SA521422031B1 (ar) مركبات 2 – فورميل – 3 – هيدروكسي فينيلوكسي ميثيل قادرة على تعديل الهيموجلوبين
EA202191630A1 (ru) ХИМИЧЕСКИ МОДИФИЦИРОВАННЫЕ КОНСТРУКЦИИ ДЛЯ RNAi И ПУТИ ИХ ПРИМЕНЕНИЯ
CL2023001268A1 (es) Composiciones farmacéuticas de un inhibidor de cinasa
CL2021002681A1 (es) Inhibidores de la dihidroorotato deshidrogenasa.
MX2022014925A (es) Moduladores de il-17a.
BR112022022578A2 (pt) Novas composições e métodos de tratar doença covid-19
BR112021024300A2 (pt) Formas de sais cristalinas de um inibidor de quinase
PH12022553019A1 (en) Il-17a modulators
GEAP202516611A (en) Nlrp3 modulators
MX2024002391A (es) Inhibidores de indolina de kif18a.
SA522441554B1 (ar) Ripk1 مركبات أيزوكسازوليدين كمثبطات واستخدامها
MX2025008092A (es) Inhibidores de kif18a y usos de los mismos
MX2023015408A (es) Inhibidores de transglutaminasas.
MX2025012370A (es) Compuesto de amida, composicion farmaceutica que comprende el compuesto y uso de esta
BR112022015925A2 (pt) Combinações de compostos beta-lactâmicos, probenecida e ácido valproico e usos dos mesmos
BR112022011527A2 (pt) Compostos e uso dos mesmos para o tratamento de deficiência de a1-antitripsina
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases
JOP20210009A1 (ar) طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله
BR112022015869A2 (pt) Composto, composição farmacêutica, métodos para inibir a ceto-hexoquinase e de tratamento e/ou prevenção de uma doença ou distúrbio, e, uso de um composto
GEAP202516217A (en) Compounds and compositions as sppl2a inhibitors